| abstract |
The present invention provides an NK1 receptor antagonist and formula (I) as a combination formulation for simultaneous or sequential administration: [Where: R 1 and R 2 are independently hydrogen, C 1-6 alkyl or C 3-6 cycloalkyl C 1-6 alkyl; or R 1 and R 2 are the nitrogen to which they are attached Taken together may form an unsubstituted 3-, 4-, 5- or 6-membered saturated ring; R 3 is C 1-6 alkyl, C 1-6 haloalkyl, C 1-3 alkoxy C 1-3 alkyl or C 1-3 haloalkoxy C 1-3 alkyl; Alternatively, R 1 and R 3 together with the atoms bonded to each other may form a saturated or unsaturated 4-6 membered ring; X is carbon or nitrogen; n is 0, 1 or 2, where, when present, R 4 is independently C 1-3 alkyl, halogen, cyano, halo C 1-3 alkyl, hydroxy, C 1-3 alkoxy and Selected from the group consisting of C 1-3 haloalkoxy; q is 1 or 2; Either R 5 or R 6 is —O—R 7 or —OCH 2 R 7 , wherein one of R 5 or R 6 is hydrogen or R 4 ; and R 7 is a phenyl ring or 5 Or a 6-membered aromatic heterocyclic ring (independently containing one or more nitrogen, sulfur or oxygen atoms), wherein the phenyl ring or heterocyclic ring is C 1-3 alkyl, Optionally substituted by one or more groups independently selected from the group consisting of halogen, cyano, haloC 1-3 alkyl, hydroxy, C 1-3 alkoxy and C 1-3 haloalkoxy] And a use of such compositions in the treatment of certain disorders, including epilepsy and mood disorders, comprising a sodium channel blocker compound or a pharmaceutically acceptable salt or solvate thereof. |